Market Synopsis:
Market Research
Future (MRFR) has projected in its latest report that the global cannula
market, valued at USD 113 Mn in 2017, is anticipated to exhibit a CAGR of 6.7%
over the forecast period 2018 to 2023. A cannula is a hollow retractable tube
which is used for removal or delivery of fluids through insertion into vein,
arteries or other body cavities. Increasing healthcare services centers in
conjunction with the rising patient population is expected to favor market
growth in the years to come.
The rising
incidences of life-threatening diseases such as cancer, liver cirrhosis,
cardiovascular diseases, diabetes, etc. have led to an exponential rise in the
demand for medical facilities. The advanced nature of these diseases has led to
an increase in demand for long-term or lifetime access to healthcare services.
This, in turn, is forecasted to augment the global cannula market over the next
couple of years.
The
exponentially rising geriatric population is expected to reflect on the growth
pattern of the healthcare sector. It is further expected to have a positive
influence on the expansion of the cannula market in the forthcoming years. On
the flip side, the factors such as lack of trained physicians and the
implementation of strict regulations are anticipated to restrict market
expansion over the next couple of years.
Market Segmentation:
By product, the global cannula
market has been segmented into cardiac cannulas, nasal cannulas, vascular
cannulas, dermatology cannulas, arthroscopy cannulas, and others.
By material, the cannula market
has been segmented into plastic (PVC), silicone and metal (stainless steel).
By application, the global
cannula market has been segmented into cardiovascular surgery, oxygen therapy,
general surgery, cosmetic/plastic surgery, orthopedic surgery, and others.
By end-user, the cannula market
has been segmented into hospitals, ambulatory surgical center, and others.
Regional Analysis:
By region, the global cannula
market has been segmented into Americas, Europe, Asia Pacific, and the Middle
East & Africa (MEA). The report indicates that the global marketplace is
set to be dominated by North America over the assessment period. Increasing
healthcare expenditure in conjunction with rising demand for medical services
is poised to revolutionize the growth trajectory of the cannula market in the
region. Furthermore, the presence ofof developed healthcare infrastructure is
poised to have a favorable impact on the expansion of the regional market.
Europe is expected to hold the
second position through the forecast period, and its growth can be ascribed to
the accelerated research & development activities. Asia Pacific is likely
to exhibit the fastest growth due to the presence of a huge patient population
in the region. It is also projected to benefit from advancements in healthcare
services in the region. MEA is prognosticated to hold the least share of the
market during the projection period.
Competitive Dashboard: for
The prominent players of the
global cannula market profiled in this MRFR report are Medtronic, Terumo
Cardiovascular Systems Corporation, Edwards Lifesciences Corporation, LivaNova
PLC, Smith & Nephew, Smiths Medical, CONMED Corporation, Teleflex Incorporated,
McKesson Medical-Surgical Inc., Boston Scientific Corporation, Harsoria
Healthcare Pvt. Ltd., ILIFE MEDICAL DEVICES PRIVATE LIMITED (INDIA), ISPG Inc.,
BD, and Denex International.
Industry News:
In April
2019, In2Bones Global, Inc., a global designer, manufacturer and distributor of
medical devices, has announced the commercial launch of ClearGuard LE™
Endoscopic Soft Tissue Release System orthopedic and podiatric surgeons in the
U.S. The product is compatible with 4mm 30° arthroscope uniportal as the clear
cannula allows unobstructed 360° panoramic arthroscopic visualization.
In October
2018, Vapotherm, Inc., a respiratory technology firm has received the FDA
approval for its Precision Flow Hi-VNI system and is preparing for its product
launch. The system leverages nasal cannula for the replacement of carbon
dioxide heavy and oxygen depleted exhaled air with humidified oxygen-rich
breathing gas.
In
September 2018, a developer of biomaterial products, Synergy Biomedical, LLC,
has received FDA 510(k) clearance for BIOSPHERE® MIS PUTTY which utilizes a
pre-loaded bone graft cannula as well as a trigger-based delivery system.
No comments:
Post a Comment